论文部分内容阅读
目的研究分析瑞舒伐他汀治疗不稳定型心绞痛对于患者血清超敏C反应蛋白(hsCRP)和血脂水平的影响。方法 110例不稳定型心绞痛患者,随机分为对照组和观察组,各55例。对照组采用辛伐他汀治疗,观察组采用瑞舒伐他汀治疗,对比两组治疗前后血脂水平和hs-CRP指标情况。结果观察组治疗后血清总胆固醇(TC)、低密度脂蛋白胆固醇(LDL-C)均显著低于对照组,差异有统计学意义(P<0.05);观察组治疗后甘油三酯(TG)、高密度脂蛋白胆固醇(HDL-C)显著高于对照组,差异有统计学意义(P<0.05);观察组治疗后hs-CRP显著低于对照组,差异有统计学意义(P<0.05)。结论瑞舒伐他汀治疗不稳定型心绞痛疗效显著,能够显著改善血脂水平,降低血清hs-CRP水平,值得推广。
Objective To investigate the effect of rosuvastatin on patients with unstable angina pectoris (C-reactive protein) and serum lipids. Methods One hundred and ten patients with unstable angina were randomly divided into control group and observation group, with 55 cases in each group. The control group was treated with simvastatin, and the observation group was treated with rosuvastatin. The blood lipid level and hs-CRP index were compared between the two groups before and after treatment. Results The levels of total cholesterol (TC) and low density lipoprotein cholesterol (LDL-C) in the observation group after treatment were significantly lower than those in the control group (P <0.05). After treatment, triglyceride (TG) , High density lipoprotein cholesterol (HDL-C) were significantly higher than the control group, the difference was statistically significant (P <0.05); hs-CRP in the observation group after treatment was significantly lower than the control group, the difference was statistically significant (P <0.05 ). Conclusion Rosuvastatin treatment of unstable angina pectoris has a significant effect, can significantly improve blood lipid levels, lower serum hs-CRP levels, it is worth promoting.